About
This forum is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.
The programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.
Publications
Upadacitinib in active non-radiographic axial spondyloarthritis: 1-year data from a double-blind, randomized, placebo-controlled, Phase 3 trial
Publications
Enthesitis and dactylitis resolution with risankizumab for active psoriatic arthritis: Integrated analysis of the randomized KEEPsAKE 1 and 2 Trials
Publications
Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
Podcasts
IMID Author Interview: Dr Jake Weddell, 2024
Podcasts
Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar
Publications
Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: Nationwide cohort study
Podcasts
IMID Author Interview: Professor Frank Verhoeven, 2024
Podcasts
Discussing PsA: 2023 EULAR recommendations and improvements in PROs with deucravacitinib
Podcasts
Discussing AxSpA: Long-term etanercept response and real-world effectiveness of tofacitinib and adalimumab
Podcasts
Discussing RA: April 2024
Publications
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
Publications
Guselkumab provides durable improvement across psoriatic arthritis disease domains: Post hoc analysis of a Phase 3, randomised, double-blind, placebo-controlled study
Publications
Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: Results from a randomized Phase 2 trial
Publications
Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the Phase 3 KEEPsAKE1 randomized clinical trial
Publications
Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: A systematic review and meta-analysis
Podcasts
Author Interview: Professor Maria Antonietta D’Agostino, 2024
Publications
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Podcasts
Author Interview: Professor Dennis McGonagle, 2024
Publications
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
Publications
"I couldn't carry on taking a drug like that": A qualitative study of patient perspectives on side effects from rheumatology drugs
Publications
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: A post hoc analysis of a Phase 3b/4 randomised safety study
Podcasts
Discussing AxSpA: Secukinumab retention over time & sacroiliac joint improvements between DMARDs
Publications
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Real-world data from the BIOBADASER registry
Podcasts
Author Interview: Dr Jürgen Rech, 2024
Podcasts
Discussing PsA: Long-term safety of ixekizumab & bimekizumab treatment in a TNFi-IR population
Podcasts
Discussing RA: March 2024
Publications
Comparative effectiveness of tofacitinib and adalimumab in axial spondyloarthritis: A real-world clinical context multicenter study
Publications
Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-Year data from SELECT-COMPARE
Publications
Long-term etanercept response for patients with radiographic axial spondyloarthritis based on achievement of early, intermediate, or late responses during index studies
Publications
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
Podcasts
Discussing AxSpA: Risk of Uveitis with Different bDMARDs & PROs following Secukinumab Treatment
Publications